日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Opportunistic Genomic Screening for Familial Hypercholesterolemia to Improve Low-Density Lipoprotein Cholesterol: A Randomized Clinical Trial

针对家族性高胆固醇血症的机会性基因组筛查以改善低密度脂蛋白胆固醇：一项随机临床试验

期刊:Jama Network Open
影响因子:
doi:10.1001/jamanetworkopen.2025.49664
Vassy, Jason L; Brunette, Charles A; Yi, Thomas; Assimes, Themistocles L; Christensen, Kurt D; Knowles, Joshua W; Sturm, Amy C; Sun, Yan V; Alexander, Nicholas; Cardellino, Mark P; Harrison, Alicia; Gerety, Haley L; Pyatt, Mary; Vered, Ron; Wilson, Peter W F; Natarajan, Pradeep; Whitbourne, Stacey B; Gaziano, J Michael; Muralidhar, Sumitra; Danowski, Morgan E
代谢
发表日期：2026
文献求助 收藏

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis

输血状况、血红蛋白水平与骨髓纤维化患者报告结局之间的关联：一项事后临床试验分析

期刊:Cancer Medicine
影响因子:
doi:10.1002/cam4.71729
Mesa, Ruben; Palmer, Jeanne M; Palandri, Francesca; Masarova, Lucia; Harrison, Claire N; Mazerolle, Flora; M'hari, Manal; Liu, Tom; Zhang, Shiyuan; Cardellino, Anna; Wang, Zhaohui; Ellis, Catherine E; Patnaik, Dwaipayan; Regnault, Antoine; LeBlanc, Thomas W
发表日期：2026
文献求助 收藏

Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)

意大利医学肿瘤学会 (AIOM) 指南在真实世界中的应用：意大利辅助和一线胰腺导管腺癌治疗的多中心调查 (GARIBALDI) 非转移性队列的生存分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.104001
Reni, M; Milella, M; Bergamo, F; Di Marco, M; Giommoni, E; Cardellino, G G; Cavanna, L; Bonomi, M; Zustovich, F; Bozzarelli, S; Salmaso, F; Spada, M; Orsi, G; Macchini, M; Insolda, J; Procaccio, L; Santoni, A; De Simone, I; Caldirola, L; Galli, F; Pinto, C
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial

年龄和性别对雷莫芦单抗联合紫杉醇作为一线奥沙利铂化疗的转换维持治疗与继续治疗的疗效和安全性的影响：ARMANI III期试验的亚组分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105329
Fazio, R; Randon, G; Bergamo, F; Palermo, F; Tamberi, S; Giommoni, E; Di Donato, S; Fornaro, L; Brunetti, O; De Vita, F; Valgiusti, M; Gobba, S M; Spallanzani, A; Murgioni, S; Bethaz, V; Strippoli, A; Latiano, T P; Cardellino, G G; Ceccon, C; Raimondi, A; Prisciandaro, M; Pircher, C C; Ambrosini, M; Manca, P; Fassan, M; Di Bartolomeo, M; Di Maio, M; Pietrantonio, F
发表日期：2025
文献求助 收藏

Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial

Bemarituzumab 作为局部晚期或转移性胃/胃食管交界处腺癌的一线治疗：随机 II 期 FIGHT 试验的最终分析

期刊:Gastric Cancer
影响因子:5.1
doi:10.1007/s10120-024-01466-w
Wainberg, Zev A; Kang, Yoon-Koo; Lee, Keun-Wook; Qin, Shukui; Yamaguchi, Kensei; Kim, In-Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet; Teixeira, Alexandra; Hitre, Erika; Udrea, Adrian A; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeño; Zahlten-Kümeli, Anita; Taylor, Kate; Enzinger, Peter C
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Development and utility of a clinical research informatics application for participant recruitment and workflow management for a return of results pilot trial in familial hypercholesterolemia in the Million Veteran Program

开发和应用临床研究信息学应用程序，用于招募参与者和管理工作流程，以开展百万退伍军人计划中家族性高胆固醇血症的结果反馈试点试验。

期刊:JAMIA Open
影响因子:3.4
doi:10.1093/jamiaopen/ooae020
Brunette, Charles A; Yi, Thomas; Danowski, Morgan E; Cardellino, Mark; Harrison, Alicia; Assimes, Themistocles L; Knowles, Joshua W; Christensen, Kurt D; Sturm, Amy C; Sun, Yan V; Hui, Qin; Pyarajan, Saiju; Shi, Yunling; Whitbourne, Stacey B; Gaziano, J Michael; Muralidhar, Sumitra; Vassy, Jason L
代谢
发表日期：2024
文献求助 收藏

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

指南在现实世界中的应用：意大利多中心胰腺导管腺癌辅助治疗和一线治疗调查。GARIBALDI 调查的初步分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100777
Reni, M; Giommoni, E; Bergamo, F; Milella, M; Cavanna, L; Di Marco, M C; Spada, M; Cordio, S; Aprile, G; Cardellino, G G; Maiello, E; Bernardini, I; Ghidini, M; Bozzarelli, S; Macchini, M; Orsi, G; De Simone, I; Rulli, Er; Porcu, L; Torri, V; Pinto, C
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care

GenoVA 研究：在初级保健中公平实施一项实用性随机试验，以评估多基因风险评分的有效性

期刊:American Journal of Human Genetics
影响因子:8.1
doi:10.1016/j.ajhg.2023.10.001
Vassy, Jason L; Brunette, Charles A; Lebo, Matthew S; MacIsaac, Katharine; Yi, Thomas; Danowski, Morgan E; Alexander, Nicholas V J; Cardellino, Mark P; Christensen, Kurt D; Gala, Manish; Green, Robert C; Harris, Elizabeth; Jones, Natalie E; Kerman, Benjamin J; Kraft, Peter; Kulkarni, Preetika; Lewis, Anna C F; Lubitz, Steven A; Natarajan, Pradeep; Antwi, Ashley A
发表日期：2023
文献求助 收藏

A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies

一套用于分析和呈现肿瘤学研究中PRO-CTCAE数据的不同方法工具箱

期刊:Jnci-Journal of the National Cancer Institute
影响因子:7.2
doi:10.1093/jnci/djad018
Regnault, Antoine; Loubert, Angély; Gorsh, Boris; Davis, Randy; Cardellino, Anna; Creel, Kristin; Quéré, Stéphane; Sapra, Sandhya; Nelsen, Linda; Eliason, Laurie
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study

DREAMM-2 研究中复发/难治性多发性骨髓瘤患者接受 belantamab mafodotin 治疗期间及治疗后的患者报告体验

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2023.1274659
Cardellino, Anna; Correll, Julia R; Martin, Mona; Gorsh, Boris; Sapra, Sandhya; Popat, Rakesh
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏